Personal Finance

Why PTC Therapeutics Stock Is Crashing Today

Man holding forehead.

What happened

Shares of the rare-disease drugmaker PTC Therapeutics (NASDAQ: PTCT) are getting pummeled today on the news that it scooped up Marathon Pharmaceuticals' politically divisive Duchenne muscular dystrophy (DMD) drug Emflaza, in a deal valued at $140 million in upfront payments, plus royalties on annual sales. PTC's stock was down by over 17% as of 2:15 p.m. EDT.

Man holding forehead.

Image Source: Getty Images.

So what

Marathon drew a wave of criticism for pricing Emflaza at a whopping $89,000 per year following its Food and Drug Administration (FDA) approval for treating DMD last month. The reason being is that Emflaza is nothing more than the generic steroid deflazacort, which costs around $1,200 a year outside of the United States.

Unfortunately for PTC and its shareholders, this pricing controversy isn't exactly fading into the background. Multiple lawmakers, after all, are now calling the drug's price into question and even the necessity of an FDA approval.

Now what

Point blank: PTC may have just got duped by Marathon. The ongoing political storm will almost certainly force PTC into slashing Emflaza's price tag sometime soon, perhaps by unprecedented levels for a newly approved prescription medicine. And the fact of the matter is that the drug is readily available online at a fraction of the cost -- although this route may not be a viable solution for many patients due to the potential legal ramifications.

In all, this double-digit sell-off is probably warranted in light of Emflaza's uncertain commercial potential, as well as the fact that PTC appears to have grossly overpaid to gain access to this controversial drug. That's why investors may want to take a step back from this specialty drugmaker today, and simply wait for the smoke to clear before deciding whether or not this pullback represents a compelling buying opportunity.

10 stocks we like better than PTC Therapeutics

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and PTC Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 6, 2017

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Personal Finance Videos

    Growth in Separately Managed Accounts and Why They Are Attractive for Financial Advisors

    Nasdaq Dorsey Wright Client Portfolio Manager Andy Hyer discusses the growth in Separately Managed Accounts and why they are attractive for financial advisors.

    5 days ago

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More